Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.

CONCLUSIONS: Veliparib plus carboplatin/gemcitabine is tolerated, with a safety profile similar to carboplatin and gemcitabine alone. Combination therapy demonstrated promising preliminary antitumor activity in platinum-sensitive ovarian cancer patients with germline BRCA mutations. Trial registration ID: NCT01063816. PMID: 29352572 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29352572?dopt=Abstract

Source: Gynecologic Oncology - January 15, 2018 Category: Cancer & Oncology Authors: Gray HJ, Bell-McGuinn K, Fleming GF, Cristea M, Xiong H, Sullivan D, Luo Y, McKee MD, Munasinghe W, Martin LP Tags: Gynecol Oncol Source Type: research